Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) is associated with significant short-term morbidity and mortality. However, survivors of AKI remain at risk for long-term adverse outcomes, including recurrent AKI, chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular events, and increased mortality. Recurrent AKI contributes to progressive renal dysfunction, cardiovascular complications, and higher mortality. Despite these risks, post-AKI follow-up care remains inconsistent. This study aimed to evaluate the occurrence of recurrent AKI and other long-term outcomes among survivors of severe AKI, comparing those managed by nephrologists with those receiving usual care.
This retrospective cohort study was conducted at a tertiary care center in Thailand. Adult patients who survived hospitalization with AKI stage 2 or 3, as defined by KDIGO criteria, were included. Patients with end-stage kidney disease on dialysis, baseline eGFR <15 mL/min/1.73 m² (CKD-EPI 2021), kidney transplantation, or terminal illnesses with life expectancy <12 months were excluded. Baseline characteristics, comorbidities, causes of AKI, and laboratory data were collected and reviewed for one year after hospital discharge (August 2022–July 2024). To minimize confounding, propensity score matching (1:2 ratio, nearest-neighbor without replacement) was performed using covariates including CKD, AKI stage, renal recovery at discharge, and discharge serum creatinine.
A total of 440 AKI survivors were included, with 100 (22.7%) receiving nephrologist follow-up and 340 (77.3%) receiving usual care. After propensity score matching, 150 patients remained (nephrologist = 50, usual care = 100), with balanced baseline characteristics.
During follow-up, the incidence rate of recurrent AKI was 69.7 and 69.9 events per 100 person-years in the nephrologist and usual care groups, respectively (HR 0.98, 95% CI 0.70–1.38, p = 0.91). After matching, the rate tended to be lower among patients followed by nephrologists (63.9 vs 72.9 events per 100 person-years; HR 0.84, 95% CI 0.49–1.45, p = 0.54), although not statistically significant.
There were no significant differences in major adverse kidney events (MAKE), major adverse cardiovascular events (MACE), or mortality between groups before or after matching. However, nephrologist follow-up was associated with a higher frequency of UACR monitoring (46.0% vs 13.8%, p < 0.001) and a trend toward lower readmission rates after matching (67.9 vs 107.7 events per 100 person-years; HR 0.64, 95% CI 0.39–1.06, p = 0.085).
Among survivors of severe AKI, follow-up by nephrologists was associated with a comparable incidence of recurrent AKI and major adverse outcomes compared with usual care. Although not statistically significant, nephrologist follow-up showed a trend toward lower readmission rates and was associated with substantially better adherence to kidney function monitoring. These findings highlight the potential value of structured nephrology follow-up in post-AKI care.
